Cash and cash equivalents = $ 477,115
Revenues = NILL
Net loss and comprehensive loss for the year = $ 3,880,397
--> Wird sich also weiterhin aus Shares finanzieren müssen...
Share Balance - September 30, 2017 = 72,054,764 Shares
Warrants Balance - September 30, 2017 = 14,693,627 Warrants; weighted average exerc.price = $0,23 (umgerechnet = 0,151 Euro)
Subsequent events;
"On November 20, 2017, the Company closed a non-brokered private placement of 7,570,500 units at a price of $0.20 per unit..."
"Subsequent to the year end 2,241,960 warrants were exercised for proceeds of $455,392 and 50,000 options were exercised for proceeds of $5,000"
Emphasis of Matter - Auditor
"Without qualifying our opinion, we draw attention to Note 1 in the consolidated financial statements which describes matters and conditions that indicate the existence of material uncertainties that may cast significant doubt about ChroMedX Corp.’s ability to continue as a going concern."
Jan 29 2018 - 22:50:53 ET - Audited annual financial statements - English
www.sedar.com/...nyDocuments.do?lang=EN&issuerNo=00007651